Evidence map›Paper›PMID 41515992›Full record

ReviewInternational journal of molecular sciences2025

The Apelinergic System in Kidney Disease: Novel Perspectives.

Sara Saladich-Cavallé, Sara Núñez-Delgado, Linhui Huo, Frederic Pons-Pellicer, Irene Martínez-Díaz, Conxita Jacobs-Cachá, Sheila Bermejo, Jordi Vilardell-Vilà, Maria José Soler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara Saladich-CavalléNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Sara Núñez-DelgadoNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Linhui HuoNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Frederic Pons-PellicerNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0009-0008-1900-4892
Irene Martínez-DíazNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0001-5849-7900
Conxita Jacobs-CacháClinical Biochemistry, Drug Delivery and Therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0003-2518-7847
Sheila BermejoNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0002-3611-4830
Jordi Vilardell-VilàNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Maria José SolerNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0003-3621-0766

Funding

Boehringer Ingelheim research grantCatalan Management Agency for University and Research Grants 2021 SGR 00883Catalan Management Agency for University and Research Grants 2021 SGR 01173China Scholarship Council (CSC) research grantInstituto de Salud Carlos III AC22/00029Instituto de Salud Carlos III FI22/00335Instituto de Salud Carlos III INT23/00078Instituto de Salud Carlos III PI21/01292Instituto de Salud Carlos III PI24/01510Instituto de Salud Carlos III PI24/01573RICORS2040 network RD21/0005/31RICORS2040 network RD24/0004/0031
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30-40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications.

Indexed as

ApelinApelin ReceptorsRenal Insufficiency, ChronicAnimalsDiabetic NephropathiesHumansRenin-Angiotensin SystemApelinApelin ReceptorsapelinAPLNRchronic kidney disease (CKD)CKD in persons with diabetesrenin–angiotensin–aldosterone system (RAS)

Identifiers

PMID41515992
PMCPMC12785970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.